Tom Schlusemann

Carboplatin/Paclitaxel can be an effective alternative for cisplatin-ineligible patients with locally advanced HNSCC

Abstract Background Despite considerable therapeutic advances, a significant evidence gap remains regarding optimal treatment strategies for cisplatin-unfit patients and whether carboplatin/paclitaxel represents a valid therapeutic alternative. This study investigates the treatme...